Jitendra Kumar Suthar

Jitendra Kumar Suthar

Auto-generated profile, based on publicly available information

Jitendra Kumar Suthar

Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Pune, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2018 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
SRSelvan Ravindran
Selvan Ravindran
JSJitendra Kumar Suthar
Jitendra Kumar Suthar
RRRutuja Rokade
Rutuja Rokade
PDPooja Deshpande
Pooja Deshpande
PSPooja Singh
Pooja Singh
SUSrushti Utekar
Srushti Utekar
Background Medical application of nanotechnology is termed as Nanomedicine and is widely used in healthcare industries. Nanotechnology has helped Physicians, Scientists and Technologists to understand the changes in cellular levels to develop nanomedicines and address the challenges faced by the healthcare sectors. Nanoparticles with less than 1nm in size have been used as drug delivery and gene delivery systems to accelerate the drug action in humans. Size of nanomaterials is akin to that of biomolecules and expected to have better interactions. Hence, its utility for various biomedical applications is explored. Objective Pharmacokinetics, metabolism, permeability, distribution and elimination studies of nanoparticles are essential to understand its potency, toxicity threshold and confirm its safe usage in humans. Reports were available for toxicity studies on nanoparticles, but work on metabolism, pharmacokinetics, distribution and permeability of nanomedicine is limited. Hence, the main focus of this review article is about metabolism, pharmacokinetics, permeability and biodistribution of nanomaterials used in nanomedicine. Conclusion Nanomedicine is increasingly becoming important in the treatment of diseases and diagnosis. Size of the particle plays an important role. As the particle size decreases its effect to cure the disease increases. Pharmacokinetics, bioavailability, half-life, metabolism, biodistribution and permeability of nanomedicine were found to be better than that of microsized drugs. In Vitro and In Vivo ADME (Absorption, Distribution, Metabolism and Excretion) studies are mandatory for pharmaceutical organic drugs. Similarly, nanomaterials should be subjected through both in vitro and in vivo ADME studies. Thus, nanomedicine can assist in the development of safe personalized medicine in humans.

7 August 2019 in Current Drug Metabolism
Verified
Journal Article
Closed access
SRSelvan Ravindran
Selvan Ravindran
ATAmlesh J. Tambe
Amlesh J. Tambe
JSJitendra K. Suthar
Jitendra K. Suthar
DCDigamber S. Chahar
Digamber S. Chahar
JFJoyleen M. Fernandes
Joyleen M. Fernandes
VDVedika Desai
Vedika Desai
Background: Nanomedicine is increasingly used to treat various ailments. Biocompatibility of nanomedicine is primarily governed by its properties such as bioavailability, biotransformation and biokinetics. One of the major advantages of nanomedicine is enhanced bioavailability of drugs. Biotransformation of nanomedicine is important to understand the pharmacological effects of nanomedicine. Biokinetics includes both pharmacokinetics and toxicokinetics of nanomedicine. Physicochemical parameters of nanomaterials have extensive influence on bioavailability, biotransformation and biokinetics of nanomedicine. Method: We carried out a structured peer-reviewed research literature survey and analysis using bibliographic databases. Results: Eighty papers were included in the review. Papers dealing with bioavailability, biotransformation and biokinetics of nanomedicine are found and reviewed. Bioavailability and biotransformation along with biokinetics are three major factors that determine the biological fate of nanomedicine. Extensive research work has been done for drugs of micron size but studies on nanomedicine are scarce. Therefore, more emphasis in this review is given on the bioavailability and biotransformation of nanomedicine along with biokinetics. Conclusion: Bioavailability results based on various nanomedicine are summarized in the present work. Biotransformation of nanodrugs as well as nanoformulations is also the focus of this article. Both in vitro and in vivo biotransformation studies on nanodrugs and its excipients are necessary to know the effect of metabolites formed. Biokinetics of nanomedicine is captured in details that are complimentary to bioavailability and biotransformation. Nanomedicine has the potential to be developed as a personalized medicine once its physicochemical properties and its effect on biological system are well understood.

29 April 2017 in International Journal of Life science and Pharma Research
Verified
Journal Article
Open access
PSPooja Singh
Pooja Singh
SRSelvan Ravindran
Selvan Ravindran
JSJitendra Kumar Suthar
Jitendra Kumar Suthar
PDPooja Deshpande
Pooja Deshpande
RRRutuja Rokhade
Rutuja Rokhade
VRVinaykumar Rale
Vinaykumar Rale
Biosurfactants belong to a well known class of microbial compounds possessing interfacial and biological activities as well as environment friendly characteristics. Recently extensive research work has been carried out by scientific community; and various novel applications of biosurfactants are being probed by industrial communities to a greater extent. This paper reviews one of the most recent applications of biosurfactants and synthesis of nanoparticles especially with respect to its application in the biomedical field. This review also emphasize the interdependent production of biosurfactants and nanoparticles.

19 September 2018
Verified
Book Chapter
Open access
PDF file
SRSelvan Ravindran
Selvan Ravindran
RRRutuja Rokade
Rutuja Rokade
JSJitendra K. Suthar
Jitendra K. Suthar
PSPooja Singh
Pooja Singh
PDPooja Deshpande
Pooja Deshpande
SUSrushti Utekar
Srushti Utekar
In vitro Biotransformation studies play a crucial role in drug discovery program that determine the fate of the new chemical entities (NCE’s). Enzyme rich matrices such as microsomes, hepatocytes, liver fractions and S9 fractions transform the new chemical entities to different metabolites. Metabolites could be pharmacologically important or toxic. Newly formed metabolites are identified using liquid chromatography interfaced with mass spectrometry. Identification of the biotransformation sites in the new chemical entity helps the medicinal chemists to optimize its structure and develop the NCE as a pharmaceutical drug. Screening pharmaceutical drugs using in vitro biotransformation studies assist in selecting the right new chemical entity for further in vivo studies in animal systems and later in human clinical trials.

5 September 2018
Verified
Book Chapter
Open access
PDF file
RRRutuja Rokade
Rutuja Rokade
SRSelvan Ravindran
Selvan Ravindran
PSPooja Singh
Pooja Singh
JSJitendra K. Suthar
Jitendra K. Suthar
Androstenedione (AD) is a steroid intermediate valuable for the production of steroid medicaments. Microbial biotransformation of phytosterol to produce AD is a well-researched area. However, low substrate solubility of phytosterol in aqueous media and nucleus degradation of AD to androstadienedione (ADD) or 9-hydroxy-AD are the major obstacles for AD production leading to detailed research for optimization of biotransformation process. In this review, microbial transformation of AD with respect to the existing methods of chemical or biochemical synthesis of AD are extensively discussed. This review examines the microbial biotransformation process and limitations for enhanced AD production. Factors affecting the effective biotransformation process to obtain AD are discussed and limitations are highlighted. The main content of this review focuses on the recent and futuristic biotechnological advances and strategies in techniques to enhance AD bioprocess.